TECELRA Receives Full FDA Approval, Expands Access to Adolescents with Synovial Sarcoma
US WorldMeds® announced that the U.S. Food and Drug Administration has granted full approval to TECELRA® (afamitresgene autoleucel), with an expanded indication that now includes eligible patients as young as 12 years old. The therapy, which received its original accelerated approval in August 2024, remains the first and only FDA-approved engineered T-cell therapy for a solid tumor cancer.
What This Approval Means
TECELRA is indicated for adult and pediatric patients 12 years of age and older with unresectable or metastatic synovial sarcoma who have received prior chemotherapy, are positive for specific HLA-A*02 subtypes, and whose tumor expresses the MAGE-A4 antigen as determined by an FDA-approved or cleared companion diagnostic. The therapy works by taking a patient’s own T-cells and genetically engineering them to recognize and attack MAGE-A4-expressing cancer cells, administered as a single infusion.
The transition from accelerated to full approval was supported by results from the SPEARHEAD-1 study, which included 137 patients and reported an overall response rate of 43.8%, including a 3.6% complete response rate. Among patients who responded to treatment, nearly a third maintained that response for 24 months or longer.
“Until today, that option was only available to adults,” said Kristen Gullo, Senior Vice President of US WorldMeds, of TECELRA’s personalized, cell-based approach. The expanded age indication means adolescents with biomarker-eligible, advanced synovial sarcoma now have access to a treatment approach that was previously unavailable to them.
Why Biomarker Testing Is the Critical First Step
Eligibility for TECELRA is determined entirely by biomarker status, which makes testing a necessary first step for any patient or family considering this option. If you or your loved one has not yet been tested, talk with your care team about:
- HLA typing – to confirm one of the eligible HLA-A*02 subtypes
- MAGE-A4 testing – to confirm tumor antigen expression, required for TECELRA eligibility
- NY-ESO-1 testing – relevant for additional treatment options and clinical trials
These biomarkers can often be assessed together through comprehensive genomic testing platforms such as Caris Life Sciences or Tempus. Not every patient will qualify for TECELRA, but knowing your biomarker status now can help identify treatment opportunities both immediately and as the treatment landscape continues to evolve.
If you need assistance or want to learn more about biomarker testing to share with your healthcare providers, visit www.sarcomabiomarkertesting.com.
Why This Matters for the SS Community
This expanded approval is significant beyond the individual patients it will treat. It extends a personalized, biomarker-driven treatment approach to an age group – adolescents – that has historically had very limited options in advanced synovial sarcoma, a disease where roughly one-third of patients are diagnosed before age 30. It also reinforces a broader shift in this disease toward treatment decisions guided by molecular testing rather than a one-size-fits-all approach.
We are grateful to the patients, families, researchers, clinicians, and advocates whose continued dedication drives progress in this rare cancer community.
For more information, visit TECELRA.com or read the full announcement. For more information about the Synovial Sarcoma Foundation, please visit our website.
